These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 15639673)
21. COX-2 inhibitors--a lesson in unexpected problems. Drazen JM N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947 [No Abstract] [Full Text] [Related]
22. [Really only Vioxx?]. Heinzl S Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229 [No Abstract] [Full Text] [Related]
23. The Vioxx debacle revisited. Mohapatra PR; Janmeja AK Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909 [No Abstract] [Full Text] [Related]
24. Merck withdraws Vioxx; FDA issues public health advisory. FDA Consum; 2004; 38(6):11. PubMed ID: 15675020 [No Abstract] [Full Text] [Related]
25. The Vioxx debacle revisited. Good CB; Kelley CL Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902 [No Abstract] [Full Text] [Related]
26. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? Messerli FH; Sichrovsky T Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380 [No Abstract] [Full Text] [Related]
27. [Vioxx: reasons for a premature retirement]. Med Sci (Paris); 2005 Jan; 21(1):35. PubMed ID: 15712385 [No Abstract] [Full Text] [Related]
29. The Vioxx debacle revisited. Daikh DI Am J Med; 2005 Sep; 118(9):1057. PubMed ID: 16164908 [No Abstract] [Full Text] [Related]
30. Vioxx doctors wooed by Merck are now its foes. Tesoriero HW Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911 [No Abstract] [Full Text] [Related]
31. Matters of the heart: assessing the cardiovascular safety of new drugs. Konstam MA Am Heart J; 2003 Oct; 146(4):561-2. PubMed ID: 14564304 [No Abstract] [Full Text] [Related]
32. The Vioxx debacle revisited. Manthous CA Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904 [No Abstract] [Full Text] [Related]
33. The lessons of Vioxx--drug safety and sales. Waxman HA N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862 [No Abstract] [Full Text] [Related]
34. Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib). Carné X; Cruz N Eur J Epidemiol; 2005; 20(2):127-9. PubMed ID: 15792277 [No Abstract] [Full Text] [Related]
35. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850 [No Abstract] [Full Text] [Related]
36. The lessons of Vioxx. Weinberg JM Cutis; 2005 Jan; 75(1):17. PubMed ID: 15732429 [No Abstract] [Full Text] [Related]
37. [Reflections on COX, Vioxx and Relifex. Increased cardiovascular risk following selective COX-2 inhibition]. Hedner T; Melander A Lakartidningen; 2004 Nov; 101(48):3938-9. PubMed ID: 15631229 [No Abstract] [Full Text] [Related]
38. VIOXX and cardiovascular events: a class effect? Berenbaum F Joint Bone Spine; 2005 Jan; 72(1):1-3. PubMed ID: 15681239 [No Abstract] [Full Text] [Related]
39. Report of specific cardiovascular outcomes of the ADVANTAGE trial. Braunstein N; Polis A Ann Intern Med; 2005 Jul; 143(2):158-9. PubMed ID: 15968005 [No Abstract] [Full Text] [Related]
40. The great rofecoxib feeding frenzy. Van Way CW JPEN J Parenter Enteral Nutr; 2005; 29(2):136-8. PubMed ID: 15772394 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]